|
End-of-day quote
Dhaka S.E.
2026-09-03
|
5-day change | 1st Jan Change | ||
| 153.20 BDT | +3.51% |
|
+5.66% | +50.05% |
| 06-26 | Beximco suspension lifted; M1 payment date extension | AN |
| 06-24 | Beximco Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 | CI |
Company Valuation: Beximco Pharmaceuticals PLC.
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 79,096 | 68,969 | 65,222 | 52,686 | 38,410 | 68,344 | - | - |
| Change | - | -12.8% | -5.43% | -19.22% | -27.1% | 77.93% | - | - |
| Enterprise Value (EV) | 86,052 | 80,148 | 74,677 | 57,836 | 38,410 | 68,344 | 68,344 | 68,344 |
| Change | - | -6.86% | -6.83% | -22.55% | -33.59% | 77.93% | 0% | 0% |
| P/E | 15.4x | 13.5x | 14.1x | 9.04x | 5.53x | 7.89x | 7.17x | 6.23x |
| PBR | 2.14x | 1.7x | 1.49x | 1.1x | - | 1.06x | 1.02x | 0.92x |
| PEG | - | -155.12x | -1.42x | 0.3x | 0.3x | 0.3x | 0.7x | 0.4x |
| Capitalization / Revenue | 2.68x | 1.99x | 1.66x | 1.19x | 0.78x | 1.25x | 1.12x | 1.01x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.25x | 1.12x | 1.01x |
| EV / EBITDA | 0x | 0x | - | 0x | 0x | 5.33x | 4.94x | 4.41x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 6.34x | 5.81x | 5.11x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 10.2x | 9.88x | 9.45x |
| FCF Yield | 4.42% | 3.33% | 5.31% | 12.1% | 11.6% | 9.83% | 10.1% | 10.6% |
| Dividend per Share 2 | 3.5 | 3.5 | 3.5 | 4 | - | 6.02 | 7.695 | 9.085 |
| Rate of return | 1.97% | 2.26% | 2.39% | 3.39% | - | 3.93% | 5.02% | 5.93% |
| EPS 2 | 11.49 | 11.48 | 10.34 | 13.07 | 15.56 | 19.42 | 21.36 | 24.58 |
| Distribution rate | 30.5% | 30.5% | 33.8% | 30.6% | - | 31% | 36% | 37% |
| Net sales 1 | 29,494 | 34,669 | 39,267 | 44,392 | 49,120 | 54,783 | 60,952 | 67,775 |
| EBITDA 1 | 7,765 | 8,543 | - | 10,668 | 11,404 | 12,829 | 13,830 | 15,494 |
| EBIT 1 | 6,651 | 6,901 | 7,216 | 8,674 | 9,848 | 10,772 | 11,759 | 13,383 |
| Net income 1 | 5,141 | 5,123 | 4,612 | 5,830 | 6,941 | 8,662 | 9,524 | 10,970 |
| Net Debt | 6,956 | 11,179 | 9,455 | 5,150 | - | - | - | - |
| Reference price 2 | 177.30 | 154.60 | 146.20 | 118.10 | 86.10 | 153.20 | 153.20 | 153.20 |
| Nbr of stocks (in thousands) | 446,112 | 446,112 | 446,112 | 446,112 | 446,112 | 446,112 | - | - |
| Announcement Date | 11/2/21 | 11/8/22 | 11/1/23 | 11/7/24 | 6/26/26 | - | - | - |
1BDT in Million2BDT
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 7.89x | - | - | 3.93% | 555M | |
| 32.72x | 11.9x | 24.26x | 0.6% | 1,024B | |
| 30.62x | - | - | 1.95% | 663B | |
| 32.73x | 7.6x | 15.8x | 2.67% | 453B | |
| 19.89x | 4.73x | 11.71x | 2.8% | 352B | |
| 22.72x | 5.84x | 14.51x | 2.7% | 304B | |
| 20.87x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.66x | 7.14x | 13.15x | 2.31% | 236B | |
| 13.33x | 4.82x | 10.06x | 3.78% | 206B | |
| -46.14x | 6.65x | 25.95x | 2.18% | 187B | |
| Average | 16.23x | 6.62x | 15.96x | 2.5% | 367.89B | |
| Weighted average by Cap. | 24.05x | 7.99x | 17.80x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BXPHARMA Stock
- Valuation Beximco Pharmaceuticals PLC.
Select your edition
All financial news and data tailored to specific country editions
